OneSource announces strong financial results in its first quarter post-listing; Q3FY25 revenues at ₹3,926 million with an EBITDA of ₹1,432 million, demonstrating a 36.5% EBITDA margin
Q3FY25 Performance Highlights Revenues of ₹3,926 million grew 18% QoQ. EBITDA grew 85% QoQ to ₹1,432 million. EBITDA margin of 36.5% grew by 1,334 basis points QoQ. Q3 FY25 normalized PAT was ₹898 million, resulting
Q3FY25 Performance Highlights
- Revenues of ₹3,926 million grew 18% QoQ.
- EBITDA grew 85% QoQ to ₹1,432 million.
- EBITDA margin of 36.5% grew by 1,334 basis points QoQ.
- Q3 FY25 normalized PAT was ₹898 million, resulting in an EPS of ₹7.8 for the quarter.
- Reported PAT was impacted by one-time OneSource setup and transaction costs.
OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter (Q3FY25) ended December 31, 2024.
Financial Highlights (In ₹ million )
| Particulars | Q3FY25 | Q2FY25 | QoQ | 9 months FY25 |
| Revenues | 3,926 | 3,340 | 18 % | 10,189 |
| Gross Margin | 3,023 | 2,240 | 35 % | 7,436 |
| Gross Margin % | 77% | 67% | 995 bps | 73% |
| EBITDA | 1,432 | 773 | 85% | 2,848 |
| EBITDA % | 36.5% | 23% | 1,334 bps | 28% |
| Normalised PAT | 898 | |||
| Normalised EPS | ₹7.8/share |
Normalised PAT = Excluding exceptional items, interest on discontinued debt & Scheme amortization
Mr. Neeraj Sharma, CEO, OneSource Specialty Pharma Limited speaking on the performance said, “We’re off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we’re on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We’re committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.”
Detailed investor communication on the performance of the Company is attached.
